WO2024240268 - CEREBELLAR PROTEIN E3 UBIQUITIN LIGASE INHIBITOR AND CHIMERIC COMPOUND TARGETING PROTEIN DEGRADATION
National phase entry:
Publication Number
WO/2024/240268
Publication Date
28.11.2024
International Application No.
PCT/CN2024/095621
International Filing Date
27.05.2024
Title **
[English]
CEREBELLAR PROTEIN E3 UBIQUITIN LIGASE INHIBITOR AND CHIMERIC COMPOUND TARGETING PROTEIN DEGRADATION
[French]
INHIBITEUR DE L'UBIQUITINE LIGASE E3 DE LA PROTÉINE CÉRÉBELLEUSE ET COMPOSÉ CHIMÉRIQUE CIBLANT LA DÉGRADATION DES PROTÉINES
[Chinese]
小脑蛋白E3泛素连接酶抑制剂及蛋白降解靶向嵌合体化合物
Applicants **
GAN & LEE PHARMACEUTICALS CO., LTD.
Inventors
XU, Fuming
CHEN, Wenmin
ZHOU, Guan
LIU, Xiaobing
DING, Yongzheng
LI, Xiaoguang
Priority Data
202310597246.0
25.05.2023
CN
202410400297.4
03.04.2024
CN
202310717359.X
16.06.2023
CN
202410398157.8
03.04.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5021 | |
| EPO | Filing, Examination, Granting | 30799 | |
| Japan | Filing, Examination, Granting | 2797 | |
| South Korea | Filing, Examination, Granting | 3397 | |
| USA | Filing, Examination, Granting | 9790 |
Total:
51,804
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides a novel human cerebellar protein (CRBN) E3 ubiquitin ligase inhibitor, capable of being used to prepare a PROTAC molecule. The CRBNE3 ubiquitin ligase inhibitor and the PROTAC molecule can be used to treat cancer and other diseases.[French]
La présente invention concerne un nouvel inhibiteur de l'ubiquitine ligase E3 de la protéine cérébelleuse humaine (CRBN), pouvant être utilisé pour préparer une molécule PROTAC. L'inhibiteur de l'ubiquitine ligase CRBNE3 et la molécule PROTAC peuvent être utilisés pour traiter le cancer et d'autres maladies.[Chinese]
本发明提供一种新的人小脑蛋白（CRBN）E3泛素连接酶抑制剂，其可用于制备PROTAC分子。CRBNE3泛素连接酶抑制剂和PROTAC分子可用于治疗癌症和其他疾病。